Trials / Completed
CompletedNCT03969550
Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 34 (actual)
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Progressive multifocal leucoencephalopathy (PML) is a demyelinating disease caused by John Cunningham virus (JCV) reactivation. Numerous molecules have been overstated because there were inaccurately tested in non-rigorous clinical trial. The objective is to draw lessons from repeatedly false hopes of unconfirmed PML treatments that might contribute to prescribing ineffective drugs on claimed efficacy in case reports or small series and by failing to respect the need for clinical trial evaluation before authorizing their widespread use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Measure of overall survival | Measure of overall survival among AR-PML (AIDS-related PML) patients, exposed or not to maraviroc (MVC), and immune reconstitution inflammatory syndrome (IRIS) onset. |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2019-05-31
- Last updated
- 2019-05-31
Source: ClinicalTrials.gov record NCT03969550. Inclusion in this directory is not an endorsement.